Further, these tumor-inhibitory effects were enhanced with the IgG2 variant of hEx3-scDb-Fc-LH compared with the IgG1 subtype, hEx3-scDb-Fc-LH (Fig. 8B). The gene discussed is PLOD1; the disease is neoplasm.